PURPOSE: Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor, widely prescribed for type 1 human immunodeficiency virus infection. A small proportion of individuals treated with NVP experience severe cutaneous adverse events, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Our aim was to verify whether genetic variability in NVP-metabolizing cytochromes or in transporter genes could be involved in susceptibility to SJS/TEN. METHODS: Twenty-seven patients with NVP-induced SJS/TEN and 78 controls, all from Mozambique, were genotyped for the ABCB1 and ABCC10 transporter genes and for CYP2B6, CYP3A4 and CYP3A5 cytochrome gene variants. A case-control and a genotype-phenotype analysis were performed. RESULTS: CYP2B6 G516T and T983C single nucleotide polymorphisms (SNPs) were found to be associated with SJS/TEN susceptibility. The 983C allele in particular was found to be highly associated with a higher risk to develop SJS/TEN [odds ratio (OR) 4.2, P = 0.0047]. The GT haplotype (wildtype for both SNPs) showed a protective effect, with an OR = 0.33 (P = 0.0016). CONCLUSIONS: This is the first study showing that genetic variability in a metabolizing enzyme can also contribute to NVP-induced SJS/TEN susceptibility.
PURPOSE: Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor, widely prescribed for type 1 human immunodeficiency virus infection. A small proportion of individuals treated with NVP experience severe cutaneous adverse events, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Our aim was to verify whether genetic variability in NVP-metabolizing cytochromes or in transporter genes could be involved in susceptibility to SJS/TEN. METHODS: Twenty-seven patients with NVP-induced SJS/TEN and 78 controls, all from Mozambique, were genotyped for the ABCB1 and ABCC10 transporter genes and for CYP2B6, CYP3A4 and CYP3A5 cytochrome gene variants. A case-control and a genotype-phenotype analysis were performed. RESULTS: CYP2B6 G516T and T983C single nucleotide polymorphisms (SNPs) were found to be associated with SJS/TEN susceptibility. The 983C allele in particular was found to be highly associated with a higher risk to develop SJS/TEN [odds ratio (OR) 4.2, P = 0.0047]. The GT haplotype (wildtype for both SNPs) showed a protective effect, with an OR = 0.33 (P = 0.0016). CONCLUSIONS: This is the first study showing that genetic variability in a metabolizing enzyme can also contribute to NVP-induced SJS/TEN susceptibility.
Authors: M C Marazzi; P Germano; G Liotta; G Guidotti; S Loureiro; A da Cruz Gomes; M C Valls Blazquez; P Narciso; C F Perno; S Mancinelli; L Palombi Journal: HIV Med Date: 2006-07 Impact factor: 3.180
Authors: C Lonjou; L Thomas; N Borot; N Ledger; C de Toma; H LeLouet; E Graf; M Schumacher; A Hovnanian; M Mockenhaupt; J-C Roujeau Journal: Pharmacogenomics J Date: 2006-01-17 Impact factor: 3.550
Authors: David W Haas; John A Bartlett; Janet W Andersen; Ian Sanne; Grant R Wilkinson; John Hinkle; Franck Rousseau; Christiana D Ingram; Audrey Shaw; Michael M Lederman; Richard B Kim Journal: Clin Infect Dis Date: 2006-08-15 Impact factor: 9.079
Authors: Neill J Liptrott; Sudeep Pushpakom; Christoph Wyen; Gerd Fätkenheuer; Christian Hoffmann; Stefan Mauss; Heribert Knechten; Norbert H Brockmeyer; Elizabeth Hopper-Borge; Marco Siccardi; David J Back; Saye H Khoo; Munir Pirmohamed; Andrew Owen Journal: Pharmacogenet Genomics Date: 2012-01 Impact factor: 2.089
Authors: Annalise M Martin; David Nolan; Ian James; Paul Cameron; Jean Keller; Corey Moore; Elizabeth Phillips; Frank T Christiansen; Simon Mallal Journal: AIDS Date: 2005-01-03 Impact factor: 4.177
Authors: Rebecca Pavlos; Simon Mallal; David Ostrov; Soren Buus; Imir Metushi; Bjoern Peters; Elizabeth Phillips Journal: Annu Rev Med Date: 2014-10-27 Impact factor: 13.739
Authors: Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips Journal: Immunol Allergy Clin North Am Date: 2017-11 Impact factor: 3.479